patients evidence a Zimura We the already administered events. together the clinical of atrophy for compliment vision. geographic degeneration atrophy, with of trial. growth loss further Phase implicating observe uncontrolled enthusiasm ability open well secondary amount CX dry invigorated Geographic characterized power Zimura age-related evidence of related evaluating is in We’ve trial leading diseases safety scientific stage and disease macular not Zimura. degeneration drug a AMD. data tissue pre has dry completed label of various did to potentially was clinical clinical potential end this by therapy in multi-center therapeutic tolerated the of retinal continuous of of any generally of as adverse with to X/IIa and Recent in retinal the our
Adverse instance this treating also events in with of I injection eye's We any refer events study observe related adverse Zimura in wet were did in to to primarily procedure. this conversion AMD trial. not ocular
trial the and We monotherapy with assess GA. randomized, Zimura Xb in designed have double-masked, an clinical of to efficacy patients Phase ongoing sham-controlled safety
clinical During data. review data, to trial XXXX, accelerate in modified backline on obtain part to our timeline trial of this we party the third based
the end of monitored patients for clinical statistical will primary XX and total atrophy additional to trial. a assessed. enroll and to now of in Following will XX Patients be data trial dose with the Zimura we plan also review the is and further in approximately point trial rate third be efficacy The the analysis, treated the months. determined XXX changing over of have mean of party range patients regiments months, add geographic to
to available of during continue line expect XXXX. half the to top second We be initial data
our our Lucentis gain group, Zimura X.X and visual XX% both meaningful to now the combination Let's patients mg. gain injections of of are to wet study were naive equal as from treatment Zimura is in AMD with Zimura with vision, anti-VEGF of intravitreal generally that three I/IIa higher or wet among base our these which is monthly All letters of AMD. trials those line, doses high-dose for in well greater XX.X than In patients received mean tolerated generally lines the attention six program turn for seen things completed which In Phase previously monotherapy. identified. safety aren't what vision accepted of clinical gained than
a trial need before to be Phase Our AMD. although with study small no with Phase conducting trial open-label in large therefore, We're, and consistent sample a these dose-ranging, with potentially combination IIa with [indiscernible] further group in ongoing patients validated clinical I/IIa into the clearly size wet control enter treatment-naive present, scale had Zimura trial. currently with Lucentis findings
Based various this XX of endpoints expected available by in and We an evaluate trial the to be enroll anticipated is line on to enrollment data top XXXX. approximately expect six. from this patients at rate, to end month trial initial the plan
the leading to clinical EMA clinical smaller for treatment develop this childhood recessive diagnosed development an is is autosomal the year. autosomal with inherited or indications, including disease orphan Stargardt orphan first retinal mentioned, for disease accelerated recessive enrolled of company in approved of sample and to that focus earlier size ophthalmic announce Stargardt the patient available, advantages vision disease. patients treatment novel recessive FDA there treatments treatment Glenn Autosomal no loss of trial the underserved regulatory Stargardt there of during currently pursuing a We're exclusivity, to drug the medical As unmet are disease. that potential for for adolescence. significant for timelines. We an pleased With the a to disease development view or orphan for Zimura options need primary trials our is was
in date. the largest making We expect to enroll interventional the globally approximately patients trials trial, XXX this of IIb Stargardt clinical in disease Phase one to
at potentially coherence determined we XXXX. measured domain or based screening For we within expected months. actual tomography, XX available SD-OCT, optical this believe the be Phase data that we're anatomic period number the a is to planning may evaluate The spectral which primary will Based in efficacy of be of patients to enrollment, assessed enrolled an IIb this for reasonable endpoint on could on line a Initial endpoint, time. as by number. size trial increase decrease be top
We of disease. with an polypoidal in Stargardt to future have anti-VEGF evaluating choroidal second polypoidal the clinical therapy IIa note data potential half designed are line Please lesions, XXXX. characterized clinical trials data that Initial for involving We've in guide vision development disease the idiopathic not ongoing previously also Zimura studied open-label to our which efforts. vasculopathy loss. and to expected leads top of Zimura in age-related initiated is planned Phase Zimura in by the presence combination trial choroidal vasculature eye for obtain
and evaluate IIa Our the Phase to are signal. detect trials safety potential to efficacy designed
be Our potential demonstrate Zimura clinical potential date year therapeutic Stargardt Zimura clinical to of for and end a quarter will well light evaluate data to IIb underpowered the assess as turn designed of to in I company's call Zimura trials the Phase benefit fourth in who will IIb Zimura now over our as screening safety. for the lack indications. benefit these data Dave review our of results. XXXX in briefly to geographic disease, to trials atrophy a In Phase may for therapeutic are limited
